CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.90
−22.55%Year over year
Reported trailing growth
- Revenue
- -64.3%
- EBITDA
- -10.8%
- EBIT
- -12.2%
- EPS
- +27.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +79.3%
- EBITDA
- +20.3%
- EPS
- +17.6%
Three-year CAGR
- Revenue
- -41.5%
- EBITDA
- —
- EBIT
- -60.8%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026